CCM
VIR icon

Camber Capital Management’s Vir Biotechnology VIR Stock Holding History

Camber Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,464
Closed -$565K – 38
2020
Q3 		$565K Buy
+16,464
New +$709K 0.03% 34

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Camber Capital Management's VIR Position: Q4 2020 in Review

Camber Capital Management sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 16,464 shares — an estimated $565K sold.

Camber Capital Management first reported a position in VIR in Q3 2020 and held it in 1 quarter. The position peaked at $565K in Q3 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

  • Camber Capital Management reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Camber Capital Management sold 16,464 Vir Biotechnology shares in Q4 2020, an estimated $565K.
  • Camber Capital Management first reported a position in Vir Biotechnology in Q3 2020 and held it in 1 quarter.
  • Camber Capital Management's Vir Biotechnology position peaked at $565K in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.